{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04626947",
      "orgStudyIdInfo": {
        "id": "STUDY19100301"
      },
      "organization": {
        "fullName": "University of Pittsburgh",
        "class": "OTHER"
      },
      "briefTitle": "Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).",
      "officialTitle": "Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD)."
    },
    "statusModule": {
      "statusVerifiedDate": "2025-06",
      "overallStatus": "TERMINATED",
      "whyStopped": "Sponsor's decision",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2021-10-14",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2024-04-24",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2024-05-31",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2020-09-29",
      "studyFirstSubmitQcDate": "2020-11-06",
      "studyFirstPostDateStruct": {
        "date": "2020-11-13",
        "type": "ACTUAL"
      },
      "resultsFirstSubmitDate": "2025-04-04",
      "resultsFirstSubmitQcDate": "2025-06-03",
      "resultsFirstPostDateStruct": {
        "date": "2025-06-05",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-06-03",
      "lastUpdatePostDateStruct": {
        "date": "2025-06-05",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR_INVESTIGATOR",
        "investigatorFullName": "David Binion, MD",
        "investigatorTitle": "Professor",
        "investigatorAffiliation": "University of Pittsburgh"
      },
      "leadSponsor": {
        "name": "David Binion, MD",
        "class": "OTHER"
      },
      "collaborators": [
        {
          "name": "Merck Sharp & Dohme LLC",
          "class": "INDUSTRY"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "The study will compare the effectiveness of Bezlotoxumab in individuals with active C. diff ( Clostridium difficile) infection who are diagnosed with Inflammatory Bowel Disease.",
      "detailedDescription": "Bezlotoxumab is administered during a course of antibiotic therapy. The dose is administered as one time treatment. Patients will receive 10 mg/kg IV over 60 minutes as a single dose via central line."
    },
    "conditionsModule": {
      "conditions": [
        "Inflammatory Bowel Diseases",
        "Ulcerative Colitis",
        "Crohn Disease",
        "C. Diff. Infections"
      ],
      "keywords": [
        "C.diff",
        "C. difficile",
        "IBD",
        "UC",
        "Bezlotoxumab",
        "Recurrent C. diff"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "PREVENTION",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 19,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Open label",
          "type": "OTHER",
          "description": "Single arm",
          "interventionNames": [
            "Biological: Bezlotoxumab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Bezlotoxumab",
          "description": "Bezlotoxumab infusion",
          "armGroupLabels": [
            "Open label"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of Participants With Recurrent C. Diff Infection at 90 Days",
          "description": "Rates of recurrent C. Diff infection defined by a positive molecular test for C. Diff and clinical symptoms.",
          "timeFrame": "90 days"
        },
        {
          "measure": "Number of Participants With Recurrent C. Diff Infection at 12 Months",
          "description": "Rates of recurrent C. Diff infection defined by a positive molecular test for C. Diff and clinical symptoms.",
          "timeFrame": "12 months"
        },
        {
          "measure": "Number of Participants With Recurrent C. Diff Infection at 24 Months",
          "description": "Rates of recurrent C. Diff infection defined by a positive molecular test for C. Diff and clinical symptoms.",
          "timeFrame": "24 months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Number of Participants With Positive Inflammatory Markers After Bezlotuxumab Infusion 90 Days",
          "description": "Rates of abnormal inflammatory markers C- Reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) after 90 days from receiving Bezlotuxumab.",
          "timeFrame": "90 days"
        },
        {
          "measure": "Number of Participants With Positive Inflammatory Markers After Bezlotuxumab Infusion 12 Months",
          "description": "Rates of abnormal inflammatory markers C- Reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) after 12 months from receiving Bezlotuxumab",
          "timeFrame": "12 months"
        },
        {
          "measure": "Number of Participants With Positive Inflammatory Markers After Bezlotuxumab Infusion 24 Months",
          "description": "Rates of abnormal inflammatory markers C- Reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) after 24 months from receiving Bezlotuxumab",
          "timeFrame": "24 months"
        },
        {
          "measure": "Quality of Life and Disease Activity Scores of Participants at Study Baseline",
          "description": "Quality of life and disease activity scores at baseline. Short Inflammatory Bowel disease questionnaire (SIBDQ) Scores range 0-70 Higher scores represent better disease related quality of life. Harvey Bradshaw Index (HBI) for CD patients and Ulcerative colitis disease activity (UCAI) for UC patients. Score ranging from 0 to 20. Patients with a score of 3 or less likely to be in remission.",
          "timeFrame": "Index visit"
        },
        {
          "measure": "Quality of Life and Disease Activity Scores of Participants After Bezlotuxumab Infusion 90 Days",
          "description": "Quality of life and disease activity scores at baseline. Short Inflammatory Bowel disease questionnaire (SIBDQ) Scores range 0-70 Higher scores represent better disease related quality of life. Harvey Bradshaw Index (HBI) for CD patients and Ulcerative colitis disease activity (UCAI) for UC patients. Score ranging from 0 to 20. Patients with a score of 3 or less likely to be in remission.",
          "timeFrame": "90 Days"
        },
        {
          "measure": "Quality of Life and Disease Activity Scores of Participants After Bezlotuxumab Infusion 12 Months",
          "description": "Quality of life and disease activity scores at baseline. Short Inflammatory Bowel disease questionnaire (SIBDQ) Scores range 0-70 Higher scores represent better disease related quality of life. Harvey Bradshaw Index (HBI) for CD patients and Ulcerative colitis disease activity (UCAI) for UC patients. Score ranging from 0 to 20. Patients with a score of 3 or less likely to be in remission.",
          "timeFrame": "12 months"
        },
        {
          "measure": "Quality of Life and Disease Activity Scores of Participants After Bezlotuxumab Infusion 24 Months",
          "description": "Quality of life and disease activity scores at baseline. Short Inflammatory Bowel disease questionnaire (SIBDQ) Scores range 0-70 Higher scores represent better disease related quality of life. Harvey Bradshaw Index (HBI) for CD patients and Ulcerative colitis disease activity (UCAI) for UC patients. Score ranging from 0 to 20. Patients with a score of 3 or less likely to be in remission.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Rates of Health Care Utilization After Bezlotuxumab Infusion 90 Days",
          "description": "Rates of ED visits and hospital admissions after Bezlotuxumab Infusion 90 Days.",
          "timeFrame": "90 Days"
        },
        {
          "measure": "Rates of Health Care Utilization After Bezlotuxumab Infusion 12 Months",
          "description": "Rates of ED visits and hospital admissions after Bezlotuxumab Infusion 12 months",
          "timeFrame": "12 months"
        },
        {
          "measure": "Rates of Health Care Utilization After Bezlotuxumab Infusion 24 Months",
          "description": "Rates of ED visits and hospital admissions after Bezlotuxumab Infusion 24 months",
          "timeFrame": "24 months"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* \\>18 years old\n* active CDI receiving therapy\n* diagnosis of IBD\n* and history of CDI.\n\nExclusion Criteria:\n\n* \\<18 years old\n* no IBD\n* no CDI\n* history of colectomy\n* history of preexisting congestive heart failure\n* pregnant or nursing women\n* TCP\\<50\n* past cardiac history.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "David Binion, MD",
          "affiliation": "University of Pittsburgh",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "University of Pittsburgh Medical Center",
          "city": "Pittsburgh",
          "state": "Pennsylvania",
          "zip": "15213",
          "country": "United States",
          "geoPoint": {
            "lat": 40.44062,
            "lon": -79.99589
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "preAssignmentDetails": "Randomly the study treatment will be offered to 50 patients.",
      "recruitmentDetails": "Patients who are part of the IBD Registry and have a defined IBD diagnosis and CDI will be approached to be consented for this study.",
      "groups": [
        {
          "id": "FG000",
          "title": "Open Label Bezlotuxumab",
          "description": "Single arm Bezlotoxumab infusion"
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "19"
                }
              ]
            },
            {
              "type": "90 Days",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "17"
                }
              ]
            },
            {
              "type": "12 Months",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "8"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "5"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "14"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Study terminated",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "14"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "groups": [
        {
          "id": "BG000",
          "title": "Open Label Bezlotuxumab",
          "description": "Single arm Bezlotoxumab infusion"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "19"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "51",
                      "spread": "12"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "12"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "7"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "American Indian or Alaska Native",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Asian",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Native Hawaiian or Other Pacific Islander",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Black or African American",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "White",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "19"
                    }
                  ]
                },
                {
                  "title": "More than one race",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Region of Enrollment",
          "paramType": "NUMBER",
          "unitOfMeasure": "participants",
          "classes": [
            {
              "title": "United States",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "19"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "IBD Type",
          "paramType": "NUMBER",
          "unitOfMeasure": "participants",
          "classes": [
            {
              "title": "Crohn's disease (CD)",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "14"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ulcerative Colitis (UC)",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "5"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Number of Participants With Recurrent C. Diff Infection at 90 Days",
          "description": "Rates of recurrent C. Diff infection defined by a positive molecular test for C. Diff and clinical symptoms.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "90 days",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "17"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Number of Participants With Recurrent C. Diff Infection at 12 Months",
          "description": "Rates of recurrent C. Diff infection defined by a positive molecular test for C. Diff and clinical symptoms.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "12 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "8"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Number of Participants With Recurrent C. Diff Infection at 24 Months",
          "description": "Rates of recurrent C. Diff infection defined by a positive molecular test for C. Diff and clinical symptoms.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "24 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "5"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Participants With Positive Inflammatory Markers After Bezlotuxumab Infusion 90 Days",
          "description": "Rates of abnormal inflammatory markers C- Reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) after 90 days from receiving Bezlotuxumab.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "90 days",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "17"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "CRP",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "6"
                    }
                  ]
                }
              ]
            },
            {
              "title": "ESR",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "8"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Participants With Positive Inflammatory Markers After Bezlotuxumab Infusion 12 Months",
          "description": "Rates of abnormal inflammatory markers C- Reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) after 12 months from receiving Bezlotuxumab",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "12 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "8"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "CRP",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            },
            {
              "title": "ESR",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Participants With Positive Inflammatory Markers After Bezlotuxumab Infusion 24 Months",
          "description": "Rates of abnormal inflammatory markers C- Reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) after 24 months from receiving Bezlotuxumab",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "24 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "5"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "CRP",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    }
                  ]
                }
              ]
            },
            {
              "title": "ESR",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Quality of Life and Disease Activity Scores of Participants at Study Baseline",
          "description": "Quality of life and disease activity scores at baseline. Short Inflammatory Bowel disease questionnaire (SIBDQ) Scores range 0-70 Higher scores represent better disease related quality of life. Harvey Bradshaw Index (HBI) for CD patients and Ulcerative colitis disease activity (UCAI) for UC patients. Score ranging from 0 to 20. Patients with a score of 3 or less likely to be in remission.",
          "populationDescription": "14 CD, 5 UC",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "Index visit",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "SIBDQ",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "19"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "40.8",
                      "spread": "14.02"
                    }
                  ]
                }
              ]
            },
            {
              "title": "HBI",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "14"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "8.6",
                      "spread": "5.2"
                    }
                  ]
                }
              ]
            },
            {
              "title": "UCAI",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "5"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "6.2",
                      "spread": "5.7"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Quality of Life and Disease Activity Scores of Participants After Bezlotuxumab Infusion 90 Days",
          "description": "Quality of life and disease activity scores at baseline. Short Inflammatory Bowel disease questionnaire (SIBDQ) Scores range 0-70 Higher scores represent better disease related quality of life. Harvey Bradshaw Index (HBI) for CD patients and Ulcerative colitis disease activity (UCAI) for UC patients. Score ranging from 0 to 20. Patients with a score of 3 or less likely to be in remission.",
          "populationDescription": "CD=12, UC=5",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "90 Days",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "17"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "SIBDQ",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "17"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "40",
                      "spread": "18.08"
                    }
                  ]
                }
              ]
            },
            {
              "title": "HBI",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "12"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "6.5",
                      "spread": "6.1"
                    }
                  ]
                }
              ]
            },
            {
              "title": "UCAI",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "5"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2.6",
                      "spread": "1.8"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Quality of Life and Disease Activity Scores of Participants After Bezlotuxumab Infusion 12 Months",
          "description": "Quality of life and disease activity scores at baseline. Short Inflammatory Bowel disease questionnaire (SIBDQ) Scores range 0-70 Higher scores represent better disease related quality of life. Harvey Bradshaw Index (HBI) for CD patients and Ulcerative colitis disease activity (UCAI) for UC patients. Score ranging from 0 to 20. Patients with a score of 3 or less likely to be in remission.",
          "populationDescription": "CD=7, UC=1",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "12 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "8"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "SIBDQ",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "8"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "49.75",
                      "spread": "18"
                    }
                  ]
                }
              ]
            },
            {
              "title": "HBI",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "7"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "7.5",
                      "spread": "5.6"
                    }
                  ]
                }
              ]
            },
            {
              "title": "UCAI",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3",
                      "spread": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Quality of Life and Disease Activity Scores of Participants After Bezlotuxumab Infusion 24 Months",
          "description": "Quality of life and disease activity scores at baseline. Short Inflammatory Bowel disease questionnaire (SIBDQ) Scores range 0-70 Higher scores represent better disease related quality of life. Harvey Bradshaw Index (HBI) for CD patients and Ulcerative colitis disease activity (UCAI) for UC patients. Score ranging from 0 to 20. Patients with a score of 3 or less likely to be in remission.",
          "populationDescription": "CD=4, UC=1",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "24 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "5"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "SIBDQ",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "5"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "61.8",
                      "spread": "6"
                    }
                  ]
                }
              ]
            },
            {
              "title": "HBI",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3.7",
                      "spread": "2.6"
                    }
                  ]
                }
              ]
            },
            {
              "title": "UCAI",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0",
                      "spread": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Rates of Health Care Utilization After Bezlotuxumab Infusion 90 Days",
          "description": "Rates of ED visits and hospital admissions after Bezlotuxumab Infusion 90 Days.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "unitOfMeasure": "Ocurrences",
          "timeFrame": "90 Days",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "17"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Hospital admissions",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    }
                  ]
                }
              ]
            },
            {
              "title": "ED visits",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "10"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Rates of Health Care Utilization After Bezlotuxumab Infusion 12 Months",
          "description": "Rates of ED visits and hospital admissions after Bezlotuxumab Infusion 12 months",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "unitOfMeasure": "Ocurrences",
          "timeFrame": "12 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "8"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "ED visits",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "6"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Hospital admissions",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Rates of Health Care Utilization After Bezlotuxumab Infusion 24 Months",
          "description": "Rates of ED visits and hospital admissions after Bezlotuxumab Infusion 24 months",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "unitOfMeasure": "Ocurrences",
          "timeFrame": "24 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Open Label Bezlotuxumab",
              "description": "Single arm Bezlotoxumab infusion"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "5"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "ED visits",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Hospital admissions",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "0",
      "timeFrame": "AE data was collected through study completion, an average of 54 weeks.",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Open Label Bezlotuxumab",
          "description": "Single arm Bezlotoxumab infusion",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 19,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 19,
          "otherNumAffected": 0,
          "otherNumAtRisk": 19
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": true,
        "restrictiveAgreement": false
      },
      "pointOfContact": {
        "title": "David G. Binion",
        "organization": "University of Pittsburgh",
        "email": "binion@pitt.edu",
        "phone": "412-647-4194"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot_SAP",
          "hasProtocol": true,
          "hasSap": true,
          "hasIcf": false,
          "label": "Study Protocol and Statistical Analysis Plan",
          "date": "2019-10-25",
          "uploadDate": "2025-04-02T15:40",
          "filename": "Prot_SAP_000.pdf",
          "size": 450143
        },
        {
          "typeAbbrev": "ICF",
          "hasProtocol": false,
          "hasSap": false,
          "hasIcf": true,
          "label": "Informed Consent Form",
          "date": "2023-06-06",
          "uploadDate": "2025-04-02T15:42",
          "filename": "ICF_001.pdf",
          "size": 411350
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-12-02",
      "submissionTracking": {
        "firstMcpInfo": {
          "postDateStruct": {
            "date": "2025-04-27",
            "type": "ACTUAL"
          }
        }
      }
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D015212",
          "term": "Inflammatory Bowel Diseases"
        },
        {
          "id": "D003093",
          "term": "Colitis, Ulcerative"
        },
        {
          "id": "D003424",
          "term": "Crohn Disease"
        },
        {
          "id": "D003015",
          "term": "Clostridium Infections"
        }
      ],
      "ancestors": [
        {
          "id": "D005759",
          "term": "Gastroenteritis"
        },
        {
          "id": "D005767",
          "term": "Gastrointestinal Diseases"
        },
        {
          "id": "D004066",
          "term": "Digestive System Diseases"
        },
        {
          "id": "D007410",
          "term": "Intestinal Diseases"
        },
        {
          "id": "D003092",
          "term": "Colitis"
        },
        {
          "id": "D003108",
          "term": "Colonic Diseases"
        },
        {
          "id": "D016908",
          "term": "Gram-Positive Bacterial Infections"
        },
        {
          "id": "D001424",
          "term": "Bacterial Infections"
        },
        {
          "id": "D001423",
          "term": "Bacterial Infections and Mycoses"
        },
        {
          "id": "D007239",
          "term": "Infections"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C000613978",
          "term": "bezlotoxumab"
        }
      ]
    }
  },
  "hasResults": true
}